A planned interim analysis of 775 patients in Merck’s study found that 7.3% of those given molnupiravir were either hospitalized or had died by 29 days after treatment, compared with 14.1% of placebo patients. There were no deaths in the molnupiravir group, but there were eight deaths of placebo patients.

Merck to Seek FDA OK for Its COVID Pill After Trial Stopped Early — https://www.medscape.com/viewarticle/960089?src=rss#vp_2

What we know — and don’t know — about Merck’s new Covid-19 pill

https://www.statnews.com/2021/10/04/what-we-know-and-dont-know-about-mercks-new-covid-19-pill/?utm_campaign=rss